Teclistamab in Relapsed or Refractory Multiple Myeloma

Cited by (1,251)

Items 401–500 of 1,251

1. Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma
   Dan T. Vogl, Shebli Atrash, Sarah A. Holstein, Omar Nadeem, Don M. Benson, Maria Chaudry, Noa Biran, Kaveri Suryanarayan, Cheryl Li, Yuyin Liu et al. · 2024 · Blood
2. Bispecific antibody and chimeric antigen receptor (CAR) modified T-cell in the treatment of multiple myeloma: Where do we stand today?
   Xiang Zhou, Klaus Martin Kortuem, Leo Rasche, Hermann Einsele · 2024 · La Presse Médicale
3. Applications of pharmacometrics in drug development
   Yuan Xiong, Mahesh N. Samtani, Danièle Ouellet · 2024 · Advanced Drug Delivery Reviews
4. Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse
   Cyrille Touzeau, Xavier P Leleu, Mourad Tiab, Margaret Macro, Aurore Perrot, Julie Gay, Carine Chateleix, Stéphane Moreau, Lionel Karlin, Caroline Jacquet et al. · 2025 · British Journal of Haematology
5. Novel Treatment Options for Multiple Myeloma
   Andrew Jay Portuguese, Rahul Kumar Banerjee, Gui Zhen Chen, Swetha Reddi, Andrew J. Cowan · 2025 · JCO Oncology Practice
6. From gene modules to gene markers: an integrated AI-human approach selects CD38 to represent plasma cell-associated transcriptional signatures
   Basirudeen Syed Ahamed Kabeer, Bishesh Subba, Darawan Rinchai, Mohammed Toufiq, Taushif Khan, Marina Yurieva, Damien Chaussabel · 2025 · Frontiers in Medicine
7. Ranking the Importance of Prognostic Factors for Relapsed/Refractory Multiple Myeloma: International Physician Panel Consensus Following a Systematic Literature Review
   Shaji Kunnathu Kumar, Xavier P Leleu, Katja Christina Weisel, Rakesh Popat, Beatrice Suero, Samantha Craigie, Paul J. Spin, Leena Patel, Abril Oliva Ramirez, Christian Hampp et al. · 2025 · Clinical Lymphoma Myeloma & Leukemia
8. Real-World Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review
   Benjamin Avi Derman, Carlyn Rose C. Tan, Ian Steinfield, Florence R. Wilson, Dee Lin, Bingcao Wu, Mariana Fernandez, Jessica Fowler, Agne Paner-Straseviciute, Nina Kim et al. · 2025 · Cancers
9. Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach
   Aarthi Kannan, K. Jeffrey, Siraj Misbah, Karthik Ramasamy · 2025 · Blood Reviews
10. Real-world effectiveness of immunoglobulin replacement for hypogammaglobulinemia and infections in multiple myeloma
    Elizabeth O’Donnell, Thais Gift, Zaid K. Yousif, Nikhil Khandelwal, Raj Desai, Lynn Y Huynh, Louise Clear, Megan Pinaire, Mingchen Ye, Azeem Banatwala et al. · 2025 · Blood Advances
11. Teclistamab Dosing in Responders: Modeling and Simulation Results from the MajesTEC-1 Study in Relapsed/Refractory Multiple Myeloma
    Yue Guo, Jin Niu, Natalia A. Quijano Cardé, Liviawati Sutjandra Wu, Xin Miao, Shalla Hanson, Yaming Su, Carlos Pérez‐Ruixo, Deeksha Vishwamitra, Katherine M. Chastain et al. · 2025 · Targeted Oncology
12. Indirect Comparison of Linvoseltamab Versus Teclistamab for the Treatment of Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
    Hans Chulhee Lee, Naresh Bumma, Joshua Ryan Richter, Jeffrey A. Zonder, James E. Hoffman, Zheng‐Yi Zhou, Viviana García-Horton, Mirko K. Fillbrunn, Hongjue Wang, Matthew Mattera et al. · 2025 · Clinical Lymphoma Myeloma & Leukemia
13. The function of GPCRs in different bone cells
    Yan Zhang, Naining Wang, Zihan Qiu, Jiahao Wang, Wen-Na An, Li-Dan Shi, Fei Chen, Dajin Zhang, Siyue Wang, Tie‐Lin Yang et al. · 2025 · International Journal of Biological Sciences
14. De-escalated Teclistamab dosing in relapsed/refractory multiple myeloma: Czech myeloma group real-world evidence analysis
    Martin Štork, Jakub Radocha, Jana Mihályová, Ivan Špıčka, Tomáš Pika, Alexandra Jungová, Ivanna Boichuk, Klara Mensikova, Jan Štraub, František Sedlák et al. · 2025 · Annals of Hematology
15. A T-cell–based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy
    Wassilis S.C. Bruins, Febe Smits, Carolien Duetz, Kaz Groen, Charlotte L.B.M. Korst, A. Vera de Jonge, Christie P.M. Verkleij, Rosa Rentenaar, Meliha Cosovic, Merve Eken et al. · 2025 · Blood
16. Real World Efficacy and Toxicity of Selinexor: Importance of Patient Characteristics, Dose Intensity and Post Progression Outcomes
    Efstathios Kastritis, Maria Gavriatopoulou, Eirini Solia, Foteini Theodorakakou, Vasiliki Spiliopoulou, Panagiotis Malandrakis, Ioannis Ntanasis‐Stathopoulos, Magdalini Migkou, Nikoleta Kokkali, Evangelos Eleutherakis‐Papaiakovou et al. · 2023 · Clinical Lymphoma Myeloma & Leukemia
17. CD46–ADC Reduces the Engraftment of Multiple Myeloma Patient-Derived Xenografts
    Michael J. VanWyngarden, Zachary J. Walker, Su Yang, Olivia Perez de Acha, Brett M. Stevens, Peter A. Forsberg, Tomer Martin Mark, William H. Matsui, Bin Liu, Daniel W. Sherbenou · 2023 · Cancers
18. Recent advances in cellular immunotherapy for lymphoid malignancies
    Haerim Chung, Hyunsoo Cho · 2023 · Blood Research
19. Upfront or Deferred Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Triplet and Quadruplet Induction and Minimal Residual Disease/Risk-Adapted Therapy
    Clifton Craig Mo, Monique A. Hartley-Brown, Shonali Midha, Paul Gerard Guy Richardson · 2023 · Cancers
20. Ethical Challenges in CAR-T slot allocation
    Beth M Faiman, Jack Khouri, Louis S. Williams · 2023 · Transplantation and Cellular Therapy
21. Integrating Immune Therapies for the Treatment of Multiple Myeloma.
    Lekha Mikkilineni, S. Sidana · 2023 · The Journal of the National Comprehensive Cancer Network
22. Arming oncolytic viruses with bispecific T cell engagers: The evolution and current status
    Yunmeng Wang, Ping Cheng · 2023 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
23. Risk of Infection in Patients With Multiple Myeloma Treated With T-Cell Redirecting Approaches: A Call Out for Clinicians
    Tommaso Lupia, Lorenzo Cani, Sara Bringhen, Francesco Giuseppe De Rosa, Benedetto Bruno, Małgorzata Mikulska, Silvia Corcione, Roberto Mina · 2024 · Clinical Lymphoma Myeloma & Leukemia
24. Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study
    Albert Oriol, Roman Hájek, Ivan Špıčka, Irwindeep Sandhu, Yael Chava Cohen, Moshe E. Gatt, José Mariz, Michèle Cavo, Jesús G. Berdeja, Kexin Jin et al. · 2024 · Clinical Lymphoma Myeloma & Leukemia
25. Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this?
    M. Martino, B. Gamberi, Elisabetta Antonioli, Sara Aquino, R. Della Pepa, L. Malerba, S. Mangiacavalli, S. Pezzatti, S. Bringhen, E. Zamagni · 2024 · Expert Review of Hematology
26. Informing the Recommended Phase III Dose of Alnuctamab, a CD3 × BCMA T‐Cell Engager, Using Population Pharmacokinetics and Exposure–Response Analysis
    Brian F. Kiesel, Mayu Osawa, Madhan Masilamani · 2024 · Clinical Pharmacology & Therapeutics
27. Efficacy and Safety of Bispecific T-Cell Engagers in Relapsed/Refractory Multiple Myeloma: A Real-World Data-Based Case-Controlled Study
    Suein Choi, Ja Min Byun, Sung‐Soo Park, Jinsun Han, Si-Eun Oh, Seungpil Jung, Hyejoon Park, Seunghoon Han, Jung Yeon Lee, Youngil Koh et al. · 2024 · Transplantation and Cellular Therapy
28. Update on B‐cell maturation antigen‐directed therapies in AL amyloidosis
    Krzysztof Jamroziak, Klaudia Zielonka, Jahanzaib Khwaja, Ashutosh D. Wechalekar · 2025 · British Journal of Haematology
29. Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis
    Gaurav Varma, Lindsay Fogel, Beth Gordon, Mateo Mejía Saldarriaga, Jaeil Ahn, Adolfo Aleman, Jessica Caro, Maya C. Rosenberg, Jorge Monge, Harsh Vallabh Parmar et al. · 2025 · Leukemia & lymphoma/Leukemia and lymphoma
30. Incidence of acute kidney injury in relapsed and refractory multiple myeloma treated with teclistamab versus CAR-T cells
    Mariam Charkviani, Maria J. Vargas-Brochero, Arjunmohan Mohan, Lisa E. Vaughan, Tyler B. Sandahl, Andre De Menezes Silva Corraes, Yi Lin, Nelson Leung, Sandra M. Herrmann · 2025 · Nephrology Dialysis Transplantation
31. Effectiveness and safety of teclistamab for relapsed or refractory multiple myeloma: a systematic review and meta-analysis
    Wenze Li, Defeng Zhao, Jiao Yu, Weilin Dong, Ziyi Wang, Xiaojing Yan · 2025 · Frontiers in Immunology
32. SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy
    Ryan Joseph Sullivan, Anthony Richard Cillo, Robert Louis Ferris, Russell William Jenkins, Harriet M. Kluger, Marleen Kok, Evan J. Lipson, Luca Paruzzo, William L. Redmond, Marco Ruella et al. · 2025 · Journal for ImmunoTherapy of Cancer
33. Real-world FDA database analysis unveiling cardiovascular adverse events associated with bispecific T cell engagers in multip myeloma
    Chang Shan, Yanli Zhang, Xinxin Zhang, Lu Li, Yanwei Chen, Ying Liu · 2025 · Scientific Reports
34. Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal Impairment Requiring Hemodialysis
    Michèle Hoffmann, Barbara Jeker, Uyen Huynh‐Do, Yara Banz, Jeanne Godau, Elisabeth Weber, Ulrike Bacher, Thomas Pabst · 2025 · Hematological Oncology
35. Management recommendations for kidney transplantation in patients with plasma cell dyscrasia
    Naoka Murakami, Christopher D. Blosser, Allison B. Webber, Gaurav Gupta, Neeraj Singh, Samhita Boppana, Samip R. Master, Raviprasenna K. Parasuraman, Erica Leigh Campagnaro, Anuja Java et al. · 2025 · Kidney International
36. TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial
    Hubert Tseng, Bhagirathbhai Dholaria, Stacey A. Cranert, Maximilian Richter, Karl Marquez, Benjamin S. Cho, Andrew Bacong, Katherine McArthur, Jeff Daniel Eskew, Joanne McCaigue et al. · 2025 · Nature Communications
37. Optimizing Tarlatamab Delivery in Small Cell and Neuroendocrine Lung Cancer: Real-World Insights into Step-Up Dosing and Prophylactic Tocilizumab Use
    Utsav Joshi, Faustine Ong, Daniel Melzer, Joanna C. Ma, Andreas Nicholas Saltos, Alberto Chiappori, Ben Creelan, Bruna Pellini, Charles Lu, Eric B. Haura et al. · 2025 · Clinical Lung Cancer
38. Next-generation T cell engagers in oncology: Pharmacologic evolution from bispecific to trispecific antibodies
    Tarek Nahle, Viraj Shah, Sami Abi Farraj, Ali Atoui · 2025 · Journal of Pharmacology and Experimental Therapeutics
39. Immunoglobulin supplementation and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamab
    Febe Smits, Kaz Groen, Charlotte L.B.M. Korst, Kris A. Frerichs, Ilse Kuipers, Sandy Kruyswijk, Maaike E. M. de Ruijter, Kazem Nasserinejad, Sonja Zweegman, Niels W.C.J. van de Donk · 2026 · Blood Cancer Journal
40. The Evolution of Chimeric Antigen Receptor T-Cell, Bispecific Antibodies and Antibody–Drug Conjugates for the Treatment of Multiple Myeloma
    Lorenzo Cani, Richa Parikh, Nisha S. Joseph, Vikas Anand Gupta, Craig C. Hofmeister, Jonathan L. Kaufman, Ajay K. Nooka, Sagar Lonial, Roberto Mina · 2026 · Clinical Lymphoma Myeloma & Leukemia
41. Harnessing the immunomodulatory effects of exercise to enhance the efficacy of monoclonal antibody therapies against B-cell haematological cancers: a narrative review
    Harrison D. Collier‐Bain, Frankie F. Brown, Adam J. Causer, Annabelle Emery, Rebecca Oliver, Sally E. Moore, James Murray, James E. Turner, John P. Campbell · 2023 · Frontiers in Oncology
42. Chimeric antigen receptor and bispecific T‐cell engager therapies in multiple myeloma patients with prior allogeneic transplantation
    Lindsay R. Hammons, Shabi Haider, Andrew Jay Portuguese, Rahul Kumar Banerjee, Anikó Szabó, Marcelo C. Pasquini, Saurabh Chhabra, Sabarinath Venniyil Radhakrishnan, Meera Mohan, Ravi Kishore Narra et al. · 2023 · British Journal of Haematology
43. BR109, a Novel Fully Humanized T-Cell-Engaging Bispecific Antibody with GPRC5D Binding, Has Potent Antitumor Activities in Multiple Myeloma
    Ying Liu, Yaqiong Zhou, Lei Nie, Shanshan Zhu, Na Li, Zhen-Hua Wu, Qi Wang, Qi Jian, Bing-Yuan Wu, Shuqing Chen et al. · 2023 · Cancers
44. Applied Cardio-Oncology in Hematological Malignancies: A Narrative Review
    Evdokia Mandala, Kyranna Lafara, Dimitrios Kokkinovasilis · 2024 · Life
45. DNA vaccines against GPRC5D synergize with PD-1 blockade to treat multiple myeloma
    Praveen Kumar Neeli, Perry Ayn Mayson Maza, Dafei Chai, Dan Zhao, Xen Ping Hoi, Keith Syson Chan, Ken H. Young, Yong Li · 2024 · npj Vaccines
46. Radiotherapy in Combination with Systemic Therapy for Multiple Myeloma—A Critical Toxicity Evaluation in the Modern Treatment Era
    Michael Oertel, Tom Schlusemann, Evgenii Shumilov, Gabriele Reinartz, A Bremer, Stephan Rehn, Georg Lenz, Cyrus Khandanpour, Hans Theodor Eich · 2023 · Cancers
47. The Expanding Clinical Role of Bifunctional Antibodies
    Dan L. Longo · 2022 · New England Journal of Medicine
48. Emerging Strategies for the Prevention of Immune Toxicities Associated with T cell–Engaging Cancer Therapies
    Andrew Kowalski, Jill Lykon, Benjamin T. Diamond, David Glen Coffey, Marcella Kaddoura, Francesco Maura, James Edward Hoffman, Dickran Gano Kazandjian, Ola Landgren · 2024 · Blood Cancer Discovery
49. Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells
    Doryan Masmoudi, Jérôme Vialaret, Christophe Hirtz, Catherine Alix‐Panabières · 2024 · Molecular Oncology
50. Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
    Jing Christine Ye, Noa Biran, Sandhya C. Nair et al. · 2024 · Clinical Lymphoma Myeloma & Leukemia
51. Challenges in the treatment of soft-tissue plasmacytoma: a retrospective analysis of 120 patients with extramedullary multiple myeloma
    Dominik Zolnowski, Simone Karp, Paul Warncke, Jessica Zinn, Marcel Pannach, Regina Herbst, Annette Hänel, Anke Morgner, Stefan Ibach, Stephan Fricke et al. · 2024 · Journal of Cancer Research and Clinical Oncology
52. Monitoring M-Protein, Therapeutic Antibodies, and Polyclonal Antibodies in a Multiparametric Mass Spectrometry Assay Provides Insight into Therapy Response Kinetics in Patients with Multiple Myeloma
    Charissa Wijnands, Peter G. A. Karel, Jolein Gloerich, Gad Armony, Anastasia Tzasta, Corrie M. de Kat Angelino, Luciano Di Stéfano, Vincent Bonifay, Theo M. Luider, Martijn M. VanDuijn et al. · 2025 · Pharmaceutics
53. Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple Myeloma
    M. Elmeliegy, A. Viqueira, E. Vandendries, Anne Hickman, U. Conte, Donald Irby, Jennifer Hibma, Hoi-Kei Lon, Joseph Piscitelli, Pooneh Soltantabar et al. · 2025 · Targeted oncology
54. Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician’s Choice of Treatment in Spain
    Cristina Encinas, Virginia Lozano, Patrick Hlavacek · 2025 · Oncology and Therapy
55. Phase 1 study of talquetamab, a humanized GPRC5D x CD3 bispecific antibody, in Japanese patients with relapsed/refractory MM
    Shinsuke Iida, Kazutaka Sunami, Shigeki Ito, Junichiro Yuda, Ei Fujikawa, Mikihiro Takamoto, Kensuke Aida, Hiroshi Yamazaki, Marimo Takahashi, Tadao Ishida · 2025 · International Journal of Hematology
56. Matching-Adjusted Indirect Comparison of Elranatamab versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma: Updated Results
    Isha Mol, Yannan Hu, Thomas William LeBlanc · 2025 · Journal of Blood Medicine
57. European Expert Panel Consensus on Outpatient Administration of Teclistamab and Talquetamab in Patients With Multiple Myeloma: Feasibility, Key Considerations, and Future Directions
    Thomas Lund, Cyrus Khandanpour, Sébastien Anguille, Jens Kisro, Maria Theresa Krauth, Johan Lund, Inger S. Nijhof, Enrique M. Ocio, Elena Zamagni, Matthieu Javelot et al. · 2025 · European Journal Of Haematology
58. Emerging role of G protein‐coupled receptor class C group 5 member D‐directed immunotherapy in multiple myeloma: Advances, resistance and combination strategies
    Xueting Wang, Yushan Cui, Yaomei Wang, Baijun Fang · 2025 · British Journal of Haematology
59. From molecular engineering to clinical applications: The expanding role of bispecific antibodies in onco-immunology
    Richard Borrelli, Luisa Brussino, Simone Matteo Negrini, Maria Felice Brizzi · 2025 · Pharmacological Research
60. Bispecific antibodies in multiple myeloma: maximizing potential through rational combination therapies
    Xiang Zhou, Johannes Moritz Waldschmidt, Hermann Einsele · 2025 · Blood Reviews
61. Belantamab mafodotin, lenalidomide, and dexamethasone for intermediate-fit and frail patients with newly diagnosed myeloma
    Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Nikolaos Kanellias, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Eirini Solia et al. · 2025 · Blood
62. The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D
    C. Riedhammer, M. Truger, H. Lee, L. Leypoldt, M. Meggendorfer, S. Hutter, H. Müller, J. Mersi, S. Kadel, T. Buchwald et al. · 2026 · Leukemia
63. Measurable residual disease in peripheral blood in myeloma: dream or reality
    Tadeusz Kubicki, Benjamin Avi Derman, Dominik Dytfeld, Andrzej J. Jakubowiak · 2023 · Current Opinion in Oncology
64. Real world analysis on the determinants of survival in primary plasma cell leukemia in the United States
    Ludovic Saba, Kevin Scott Landau, Hong Liang · 2023 · Leukemia
65. Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma
    Donald C. Moore, Katelynn Granger, Hailey Hill, Allison Karabinos, James A. Davis · 2024 · Expert Review of Hematology
66. Personalized Treatment of Multiple Myeloma in Frail Patients
    Jodi J. Lipof, Nadine H. Abdallah, Brea C. Lipe · 2024 · Current Oncology Reports
67. Activating adaptive immunity by bispecific, T-cell engager antibodies bridging infected and immune-effector cells is a promising novel therapy for chronic hepatitis B
    Zhe Xie, Ulrike Protzer · 2024 · Antiviral Research
68. Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study
    Niels W.C.J. van de Donk, Nizar Jacques Bahlis, Luciano J. Costa et al. · 2024 · Blood Cancer Journal
69. Outcomes of frailty subgroups of older adults (age ≥ 70) treated with teclistamab: an International Myeloma Foundation immunotherapy database real-world analysis
    Hira S. Mian, Thomas G Martin, Gregory R. Pond et al. · 2025 · Leukemia
70. Bispecific Antibodies, Nanobodies and Extracellular Vesicles: Present and Future to Cancer Target Therapy
    Asier Lizama-Muñoz, Julio Plaza‐Díaz · 2025 · Biomolecules
71. Trial designs and endpoints for immune therapies in multiple myeloma
    Guido Lancman, Erin L Moshier, Hearn Jay Cho, Samir Sunil Parekh, Shambavi Richard, Joshua Ryan Richter, Cesar Rodriguez, Adriana Rossi, Larysa Jessica Sanchez, Sundar Jagannath et al. · 2022 · American Journal of Hematology
72. Cyclophosphamide etoposide dexamethasone as salvage and bridging therapy in relapsed refractory and extramedullary multiple myeloma
    Joseph Kauer, Lilli Sophie Sester, Katharina Kriegsmann, Niels Weinhold, Michael Christoff Ober, Carsten Müller‐Tidow, Hartmut Goldschmidt, Marc‐Steffen Raab, Sandra Sauer · 2023 · Hematological Oncology
73. SOHO State of the Art Updates and Next Questions | BCMA-Directed CAR T-Cells: Early Results and Future Directions
    E. Biltibo, J. Berdeja · 2023 · Clinical Lymphoma, Myeloma & Leukemia
74. Bridging the Gap: Early Transition and Hybrid Models of Care to Improve Access to Chimeric Antigen Receptor T Cell Therapy
    Nausheen Ahmed, Zahra Mahmoudjafari, Mehdi Hamadani, Hamza Hashmi · 2023 · Transplantation and Cellular Therapy
75. Current Main Topics in Multiple Myeloma
    Sonia Morè, Laura Corvatta, Valentina Maria Manieri, Attilio Olivieri, Massimo Offidani · 2023 · Cancers
76. Reinforced antimyeloma therapy via dual-lymphoid activation mediated by a panel of antibodies armed with bridging-BiTE
    Tatsuya Konishi, Toshiki Ochi, Masaki Maruta, Kazushi Tanimoto, Yukihiro Miyazaki, Chika Iwamoto, Takashi Saitou, Takeshi Imamura, Masaki Yasukawa, Katsuto Takenaka · 2023 · Blood
77. A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma
    Shonali Midha, Monique A. Hartley-Brown, Clifton Craig Mo, Shahrier Hossain, Omar Nadeem, Elizabeth O’Donnell, Giada Bianchi, Adam Samuel Sperling, Jacob P. Laubach, Paul Gerard Guy Richardson · 2023 · Expert Opinion on Drug Safety
78. Rare oncology therapeutics: review of clinical pharmacology package of drug approvals (2019–2023) by US FDA, best practices and recommendations
    Amitava Mitra, Jong Bong Lee, Douglas Steinbach, Anasuya Hazra, Rajesh Krishna · 2023 · Journal of Pharmacokinetics and Pharmacodynamics
79. Risk factors and clinical impact of cytomegalovirus DNAemia in patients with multiple myeloma treated with teclistamab
    Charles Pei, Zeinab El Boghdadly, Lisa M. Blackburn, Nidhi Sharma, Naresh Bumma, Abdullah Khan, Srinivas S. Devarakonda, Elvira R. Umyarova, Don Benson, Ashley Elizabeth Rosko et al. · 2025 · Blood Neoplasia
80. Targeting B Cells for the Treatment of Idiopathic Inflammatory Myopathy
    Tao Liu, Bo Chen, Geng Yin · 2025 · Clinical Reviews in Allergy & Immunology
81. Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization
    Jenna R. Puttkammer, Jason N. Barreto, Chelsee J. Jensen, Adrienne N. Nedved, Justine L. Wilson-Miller, Kristin C. Mara, Lucy M. Holmes, Allison R. Kosobud, Prashant Kapoor, Morie Abraham Gertz et al. · 2025 · JCO Oncology Practice
82. Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: a real-world experience
    Malin L. Hultcrantz, Andriy Derkach, Hani Hassoun, Neha Korde, Kylee H. Maclachlan, Sham Mailankody, Dhwani Patel, Urvi Ashok Shah, Carlyn Rose C. Tan, David J. Chung et al. · 2025 · Blood Neoplasia
83. T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS
    Katia Mancuso, Marco Talarico, Enrica Manzato, Simona Barbato, Paola Tacchetti, Elena Zamagni, Michèle Cavo · 2025 · Cancers
84. Characterization and comparative analysis of multifunctional natural killer cell engagers during antitumor responses
    Hang Lin, Ryan B. Case, Kathy Y. Wei, Ittai E. Eres, Benjamin M. Alba, Joelle Kaner, Yen-Chi Wu, Tracy Yamawaki, Mina Mostafavi, Hong Zhou et al. · 2025 · Cell Reports Medicine
85. Using bispecific antibodies in a patient with peritoneal dialysis for relapsed multiple myeloma
    Heng Jiang, Yagya Ahlawat, Amir S. Steinberg · 2025 · Journal of Oncology Pharmacy Practice
86. High-Risk Genetic Multiple Myeloma: From Molecular Classification to Innovative Treatment with Monoclonal Antibodies and T-Cell Redirecting Therapies
    D. De Novellis, P. Scala, Valentina Giudice, C. Selleri · 2025 · Cells
87. Optimization of a Novel 2 + 2 BCMA × CD3 Bispecific Antibody for Minimized Cytokine Release and Potent Efficacy
    Danqing Wu, Lini Huang, Naren Gaowa, Rui Zhang, Shiyong Gong, Xuan Wu, Chengbin Wu · 2025 · Molecular Cancer Therapeutics
88. Recommended Phase II Doses of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma From MonumenTAL‐1: Clinical Pharmacology Results
    Jue Gong, Jie Zhou, Dongfen Yuan, Xuewen Ma, Deeksha Vishwamitra, Brandi W. Hilder, Tara J. Masterson, Jaszianne A. Tolbert, Thomas M. Renaud, Christoph Johann Heuck et al. · 2025 · Clinical Pharmacology & Therapeutics
89. Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy
    Jennifer H. Cooperrider, Benjamin Avi Derman · 2025 · Drugs
90. Efficacy and safety of bispecific antibodies in multiple myeloma patients with end-stage renal disease undergoing hemodialysis: a case report of elranatamab and a literature review
    Daisuke Ogiya, Rikio Suzuki, Shun Goto, Yosuke Nakagawa, Miina Nasukawa, Shino Iwata, Hidetsugu Kawai, Masako Toyosaki, Shinichiro Machida, Makoto Onizuka et al. · 2025 · Annals of Hematology
91. Composition and Functional State of T and NK Cells in the Extramedullary Myeloma Tumor Microenvironment
    Anjana Anilkumar Sithara, V. Kapustová, D. Žihala, O. Venglar, D. Bilek, M. Helal, M. John, E. Radova, L. Broskevicova, J. Vrána et al. · 2025 · Blood Cancer Discovery
92. Preemptive Immunoglobulin Prophylaxis Reduces Infections in Patients Treated With Anti-BCMA Bispecific Antibodies
    Bénédicte Piron, Laura Rodrigo, Benoît Tessoulin, Thomas Gastinne, Viviane Dubruille, Valentin Letailleur, Chloé Antier, Anne Lok, Estelle Leroy, Philippe Moreau et al. · 2025 · Clinical Lymphoma Myeloma & Leukemia
93. Talquetamab for the treatment of relapsed/refractory multiple myeloma: a review of efficacy, safety, and real-world evidence
    Donald C. Moore, Grace Elsey, Jessica McElwee, Shebli Atrash · 2025 · Expert Opinion on Biological Therapy
94. Extramedullary Disease—Achilles Heel in Myeloma?
    Shaji Kunnathu Kumar, Joshua Ryan Richter, Saad Z. Usmani, Yael Chava Cohen, J. Christine Ye, María‐Victoria Mateos, Vânia Hungria, Elena Zamagni · 2025 · American Journal of Hematology
95. BCMA-CD3 T-cell engager as salvage therapy for multirefractory primary immune thrombocytopenia
    Jesús Duque‐Afonso, Christoph Rummelt, Katharina Förster · 2026 · The Lancet
96. T cell exhaustion in bi- and trispecific T cell engager therapy in hematologic malignancies: Mechanisms and implications
    Amelie Muth, Alessandra M. E. Holzem, Anne-Sophie Neumann, Veit Bücklein, Marion S. Subklewe, Nora Philipp · 2026 · Med
97. B‐cell maturation antigen expression and clinical features of plasmablastic lymphoma
    Ning C. Dong, Hailing Zhang, Jinming Song et al. · 2024 · eJHaem
98. Enhancing anti-CD274 (PD-L1) targeting through combinatorial immunotherapy with bispecific antibodies and fusion proteins: from preclinical to phase II clinical trials
    Dominik Kiem, Matthias Ocker, Richard Greil, Daniel Neureiter, Thomas Melchardt · 2024 · Expert Opinion on Investigational Drugs
99. Bispecific Antibodies for Multiple Myeloma: Recent Advancements and Strategies for Increasing Their Efficacy
    Moran Wang, Chaofan Wang, Jun Deng, Huafang Wang, Chunyan Sun, Shanshan Luo, Yu Hu · 2024 · Frontiers in Bioscience-Landmark
100. Targeting GPRC5D With Talquetamab: A New Frontier in Bispecific Antibody Therapy for Relapsed/Refractory Multiple Myeloma
     Jacob Shaver, Daniel Horton, Zachery Halford · 2024 · Annals of Pharmacotherapy